Miscellaneous Malignancies | Norton Healthcare

Indication: Miscellaneous Malignancies

An open-label, Phase II, platform trial evaluating safety and efficacy of multiple BI 754091 anti-PD-1 based combination regimens in PD-(L)1 naïve and PD-(L)1 pretreated patient populations with advan

Sub-indication: Miscellaneous Malignancies

Drug Study

Principal Investigator: John Hamm, M.D.
Norton Cancer Institute

Sponsor: Boehringer Ingelheim

Learn more at ClinicalTrials.gov

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.